Sézary syndrome

It is a cutaneous T-cell lymphoma — a cancer of lymphocytes, the white blood cells of the immune system, that involves the skin. It is not a skin cancer: skin cancer develops from skin cells, and this develops from immune cells.

It is defined by three things together: redness covering at least 80% of the body surface, swollen lymph nodes in several regions, and the same abnormal T cells present in the skin, the lymph nodes and the blood.

The blood is what separates it from the more common skin lymphoma, mycosis fungoides. Diagnosis requires a clone of T cells detectable in the bloodstream and at least 1,000 of these cells in every microlitre of blood.

The cells themselves have a distinctive appearance under the microscope — a deeply folded nucleus, described as brain-like.

It is not what mycosis fungoides usually turns into. In one study, only 3% of 1,422 people progressed from that condition to this one over a median of 14.5 years. Sézary syndrome usually arises in its own right.

It is very rare — roughly one twenty-fifth as common as mycosis fungoides.

The cause is not known. None of the sources we read states an established cause.

Nothing in these sources describes it as inherited or as contagious, and because this is a lymphoma rather than a skin cancer, sun exposure is not a cause.

Recorded incidence rises steeply with age, and differs by sex and ethnicity in US registry data. Those are patterns in what registries record rather than causes, and they are shaped partly by access to specialist dermatology.

The skin turns red over almost the whole body, and it scales. That is the state the sources call erythroderma, and living inside it affects sleep, temperature regulation and the ability to be comfortable in ordinary clothes.

Itch is the dominant symptom. One review reports it in every person with this condition and describes it as intractable — a word chosen carefully by clinicians and worth passing on rather than softening.

The skin on the palms and soles thickens and cracks. The lower eyelids can turn outward.

The skin stops working as a barrier, and infection risk becomes a core part of the illness rather than an occasional complication. Cancer Research UK links the weakened immune system in this condition directly to that risk.

It is aggressive. The NCI gives a median survival of about four years, and a 2023 review reports five-year survival of 40% to 50% without naming a single cohort behind it. Those are group figures from populations treated over past decades and they cannot tell any one person what will happen.

Because whole-body redness is the defining feature, one of the mainstay treatments works on the blood itself. Blood is drawn, the white cells are separated out, treated with a light-sensitising drug and ultraviolet light, and returned to the body.

Alongside that, drugs given through the whole body are used: interferon, retinoid drugs, and several targeted antibodies — including one aimed at a receptor these lymphoma cells carry, licensed for this condition and for mycosis fungoides — as well as conventional chemotherapy.

Skin-directed treatment still has a role in managing symptoms, and controlling the itch is treated as a goal in itself rather than an afterthought.

A donor stem cell transplant is part of the conversation here in a way it is not for early-stage skin lymphoma, and that is covered in the next section.

A transplant using the person’s own cells has no established role in this disease. Reported responses are frequently short-lived, and the EBMT recommendations for these lymphomas do not address it at all.

Whole-body redness, scaling, thickened cracking palms and soles, and relentless itch. This is a condition that is on a person all the time, visible and uncomfortable, and none of the sources we read attempts to measure what that does to people.

Infection risk shapes daily life, because the skin that normally keeps things out has stopped doing it.

Care is shared between dermatology and haematology from early on, unlike in early-stage skin lymphoma where dermatology leads.

Treatment is ongoing rather than a course with an end date, and it is aimed as much at making the person comfortable as at controlling the lymphoma.

For those who go to a transplant, it means a donor search, conditioning treatment, and a period with essentially no immune system in someone whose skin barrier is already failing. It is offered only to people fit enough for it.

This is one of the diseases in this library where a donor genuinely matters, and where it matters from the beginning rather than after a relapse.

EBMT’s 2025 recommendations state that people with Sézary syndrome should be considered for a donor transplant regardless of which line of treatment they are on. That is because the disease is advanced by definition — there is no early stage of it to wait through.

And unlike almost every other lymphoma in this library, the transplant here means someone else’s cells. The treatment works through the donor’s immune system recognising and attacking the lymphoma, which is something a person’s own cells cannot do. Cancer Research UK puts it plainly: for this group of lymphomas you usually have stem cells or bone marrow from another person.

A matched brother or sister is preferred where one exists. Where one does not, a well-matched unrelated donor from a registry is used, and one specialist cohort found outcomes comparable between the two.

We are going to state the outcomes rather than leave you to assume them, because the guidelines describe a donor transplant as the one potentially curative treatment for advanced disease and that phrase, on its own, promises far more than the evidence supports.

Very few people have one. Both Cancer Research UK and Lymphoma Action describe it as something a few people with advanced disease have, and only those fit enough.

So the honest position is this: if you are considering joining a registry, someone with this diagnosis is among the people who may need you. There are not many of them, the transplant is hard, and it works for a minority. All three of those things are true at once.